Search results for "phosphonate"

showing 10 items of 372 documents

A Novel 1D-AF Hybrid Organic-Inorganic Chromium(II) Methyl Phosphonate Dihydrate: Synthesis, X-Ray Crystal and Molecular Structure, and Magnetic Prop…

2010

Light-blue crystals of chromium(II) methyl phosphonate dihydrate, [Cr(CH(3)PO(3))(H(2)O)].H(2)O, were obtained in water by mixing filtered solutions of methylphosphonic acid and chromium(II) chloride in the presence of urea in an inert atmosphere. The compound was characterized by elemental analysis, TGA-DSC, X-ray crystallography, magnetic measurements, and UV-visible and FT-IR spectroscopies. The crystal and molecular structures (orthorhombic Pnma (no. 62): a = 4.4714(5) A, b = 6.8762(7) A, c = 19.180(2) A, Z = 4) have been solved using single-crystal X-ray diffraction. The chromium(II) ion is six-coordinated by oxygens (4 + 2) to form an elongated octahedron, with the four equatorial oxy…

Inorganic chemistrychemistry.chemical_elementChromophorePhosphonateInorganic ChemistryMetalCrystalchemistry.chemical_compoundChromiumCrystallographychemistryvisual_artvisual_art.visual_art_mediumMoleculeOrthorhombic crystal systemPhysical and Theoretical ChemistryMethylphosphonic acid
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct

CBCT in the diagnosis of osteonecrosis of the jaws

2013

Short Summary: ONJ is associated with bisphosphonates, and recently with antiangiogenic drugs. Another cause is radiotherapy. Few papers have previously investigated the value of CBCT in the diagnosis of ONJ. Purpose/Objectives: To describe the CBCT findings in the diagnosis of osteonecrosis of the jaws (ONJ) according to a new staging system of ONJ. Methods and Materials: 9 patients (5 women, 4 men, 54-76 yrs.) affected by ONJ were studied with a CBCT device (90 kV, 12.5 mA, 0.25 mm voxel size) in 2012-2013. 7/9 patients were treated with bisphosphonates (5 for bone metastasis, 2 for osteoporosis), 1/9 patient was treated with an antiangiogenic drug, 1/9 patient received radiotherapy. Pati…

JawbiphosphonateOsteonecrosisCBCTantiangiogenic
researchProduct

Alkyl-Substituted Aminobis(phosphonates)Efficient Precipitating Agents for Rare Earth Elements, Thorium, and Uranium in Aqueous Solutions

2021

The efficient and environmentally sustainable separation process for rare earth elements (REE), especially for adjacent lanthanoids, remains a challenge due to the chemical similarity of REEs. Tetravalent actinoids, thorium, and traces of uranium are also present in concentrates of REEs, making their separation relevant. This study reports six simple water-soluble aminobis(phosphonate) ligands, RN[CH2P(O)(OH)2]2 (1 R = CH2CH3, 2 R = (CH2)2CH3, 3 R = (CH2)3CH3, 4 R = (CH2)4CH3, 5 R = (CH2)5CH3, 6 R = CH2CH(C2H5)(CH2)3CH3) as precipitating agents for REEs, Th, and U, as well as gives insight into the coordination modes of the utilized ligands with REEs at the molecular level. Aminobis(phospho…

LanthanideAqueous solutionLigandGeneral Chemical EngineeringInorganic chemistrychemistry.chemical_element02 engineering and technologyGeneral Chemistry010402 general chemistry021001 nanoscience & nanotechnology01 natural sciencesPhosphonate0104 chemical sciencesSeparation processchemistry.chemical_compoundChemistryDeprotonationchemistryTitrationScandium0210 nano-technologyQD1-999ACS Omega
researchProduct

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

2013

Abstract Background We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). Methods This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. Results The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (r…

LeiomyosarcomaOncologymedicine.medical_specialtyMetastasis; bone; sarcoma; prognosis; soft tissuesarcomaBone diseaseSettore MED/06 - Oncologia MedicaSkeletal related eventsboneMetastasisBiphosphonateBiphosphonateInternal medicinemedicineAngiosarcomaSoft tissue sarcomabusiness.industrySoft tissue sarcomaResearchBone metastasesSoft tissueRetrospective cohort studymedicine.diseaseBone metastases Soft tissue sarcoma Skeletal related events BiphosphonateSurgeryOncologySarcomaprognosisbusinesssoft tissue
researchProduct

NMR, potentiometric and ESI-MS combined studies on the zinc(II) magnesium(II) and calcium(II) complexation by (morpholin-1-yl)methane-1,1-diphosphoni…

2012

Abstract The crystal structures of the two derivatives of aminomethane-1,1-diphosphonic acid with morpholinyl- (1) and thiomorpholinyl- (2) side chains were determined by single crystal X-ray diffraction and discussed with respect to molecular geometry and solid state organization. The protonation equilibria, solution behavior and complex-formation equilibria in solutions of 1 and 2 with the Zn(II), Mg(II) and Ca(II) ions were studied by means of NMR, pH-potentiometry and ESI-MS methods. As the p K ( NH + ) protonation constants of 1 and 2 are high (11.65 and 11.91, respectively) two different approaches were used to evaluate the pH-potentiometric data. The first approach disregarded the pr…

LigandInorganic chemistryPotentiometric titrationThio-chemistry.chemical_elementProtonationCrystal structureZincPhosphonateMedicinal chemistryInorganic Chemistrychemistry.chemical_compoundMolecular geometrychemistryMaterials ChemistryPhysical and Theoretical ChemistryPolyhedron
researchProduct

Evaluation of the sequestering ability of different complexones towards Ag+ ion

2014

Abstract The interaction between Ag+ cation and different ligands was evaluated as a function of temperature and ionic strength by means of potentiometric techniques. Six aminopolycarboxylic (APCs) and aminopolyphosphonic (APPs) ligands were chosen, namely four APCs: nitrilotriacetic acid (NTA), ethylene-glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), ethylenediamine-N,N,N’,N’-tetraacetate (EDTA) and diethylenetriamine-N,N,N’,N”,N”-pentaacetic acid (DTPA)] and two APPs: [(1-hydroxyethane-1,1-diyl)bis(phosphonic acid) (HEDP) and [[(Phosphonomethyl)imino]bis[2,1-ethanediylnitrilobis(methylene)]] tetrakis-phosphonic acid (DTPP). Different mononuclear species with general formu…

LigandPotentiometric titrationInorganic chemistryNitrilotriacetic acidCondensed Matter PhysicsSilver aminipolycarboxylates aminopolyphosphonates ionic strength sequestration.Atomic and Molecular Physics and OpticsElectronic Optical and Magnetic MaterialsIonMetalchemistry.chemical_compoundchemistryStability constants of complexesIonic strengthvisual_artMaterials Chemistryvisual_art.visual_art_mediumSettore CHIM/01 - Chimica AnaliticaPhysical and Theoretical ChemistryMethyleneSpectroscopy
researchProduct

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

2014

Long-lasting HBV-DNA suppression is considered to be the best surrogate end-point of antiviral therapy in patients with hepatitis B virus (HBV) related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related complications and improve survival. Treatment with oral antiviral drugs in patients with HBV cirrhosis is effective in restoring liver function and improving survival even in those with decompensated cirrhosis. These agents are generally well-tolerated for long-term treatment, and several evidences have demonstrated that they are able to reverse liver fibrosis and prevent the occurrence of HCC.

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularGuanineLiver fibrosisOrganophosphonatesAdministration Oralmedicine.disease_causeGastroenterologyAntiviral AgentsFibrosisInternal medicinemedicineHumansIn patientTenofovirHepatitis B virusTelbivudineHepatologybusiness.industryAdeninecirrhosisLiver NeoplasmsAntiviral therapyNucleosidesmedicine.diseaseHepatitis BFibrosisdigestive system diseasesLamivudineHepatocellular carcinomaLiver functionbusinessThymidine
researchProduct

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop

2011

Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the…

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drug
researchProduct

Platelet-Rich Plasma (PRP) in Dental Extraction of Patients at Risk of Bisphosphonate-Related Osteonecrosis of the Jaws: A Two-Year Longitudinal Study

2020

: Dental extraction has often been described as the main trigger event of osteonecrosis of the jaws (ONJ). This longitudinal hospital-based study aimed to evaluate the outcome at 2 years of a standardized medical-surgical protocol for dental extraction, combined with platelet rich-plasma (PRP) application, compared with conventional protocol not combined with PRP or any other autologous platelet concentrate in cancer (ONC) and osteometabolic (OST) patients, at risk of bisphosphonate (BP)-related ONJ. Twenty patients were consecutively recruited: six received BPs for cancer skeletal-related events (34.17 &plusmn

Longitudinal studymedicine.medical_specialtybisphosphonatePRPmedicine.medical_treatmentONJosteonecrosis of the jawslcsh:TechnologyMetabolic bone diseaselcsh:Chemistry03 medical and health sciences0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineGeneral Materials ScienceAutologous plateletProspective cohort studyInstrumentationbisphosphonateslcsh:QH301-705.5Fluid Flow and Transfer Processesbusiness.industrylcsh:TProcess Chemistry and TechnologyGeneral EngineeringCancerplatelet-rich plasma030206 dentistryBisphosphonatemedicine.diseaselcsh:QC1-999Computer Science Applicationsosteonecrosis of the jawDental extractionlcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040030220 oncology & carcinogenesisPlatelet-rich plasmadental extractionbusinesslcsh:Engineering (General). Civil engineering (General)lcsh:PhysicsApplied Sciences
researchProduct